Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study.

@article{Hoang2013DesiccatedTE,
  title={Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study.},
  author={Thanh Duc Hoang and Cara Olsen and Vinh Quang Mai and Patrick W. Clyde and Mohamed K M Shakir},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2013},
  volume={98 5},
  pages={
          1982-90
        }
}
CONTEXT Patients previously treated with desiccated thyroid extract (DTE), when being switched to levothyroxine (L-T₄), occasionally did not feel as well despite adequate dosing based on serum TSH levels. OBJECTIVE Our objective was to investigate the effectiveness of DTE compared with L-T₄ in hypothyroid patients. DESIGN AND SETTING We conducted a randomized, double-blind, crossover study at a tertiary care center. PATIENTS Patients (n = 70, age 18-65 years) diagnosed with primary… 

Figures and Tables from this paper

Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study.
TLDR
The combination therapy yielded significantly lower free T4 levels, with no changes in TSH or T3 levels, and no clear clinical benefit of the studied formulation could be observed.
Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism
TLDR
Those patients that were most symptomatic on LT4 preferred and responded positively to therapy with LT4 + LT3 or DTE, and strong preference for treatment containing T3, which improved performance on TSQ-36, GHQ-12, BDI, and visual memory index (VMS-IV component).
Conversion to Armour Thyroid from Levothyroxine Improved Patient Satisfaction in the Treatment of Hypothyroidism
TLDR
AT treatment was preferred over LT4 replacement therapy by 78% of patients with hypothyroidism in the sub-group with persistent subjective complaints while on T4-only therapy, suggesting AT could be a reasonable alternative choice for treating this sub- group of patientswith hypothy thyroid disease.
LIOTHYRONINE AND DESICCATED THYROID EXTRACT IN THE TREATMENT OF HYPOTHYROIDISM.
TLDR
Newly diagnosed hypothyroid patients should be treated withLT4, and a trial of combination therapy with LT4+LT3 can be considered for those patients that have unambiguously not benefited from LT4.
Management of Patients Symptomatically Unresponsive to Levothyroxine: Natural Desiccated Thyroid Extract or the Combination of Levothyroxine and Liothyronine? A Research Priority.
  • A. HealdM. LivingstonD. Hughes
  • Medicine, Biology
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • 2019
TLDR
Key deficiencies in the existing evidence-base together with improved understanding of the pharmacology of levothyroxine resistance, indicates that now is the right time for a definitive clinical trial to address this important area of uncertainty.
The relevance of T3 in the management of hypothyroidism.
Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association
TLDR
The aim of the present position statement was to define the correct clinical indications, schedule, duration of treatment and contraindications of combined treatment with L-T4 and L- T3 in hypothyroid patients in an attempt to guide clinicians and to avoid potential adverse effects of overtreatment.
Pharmacokinetics of Liothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal.
TLDR
The PK of LT3 is well described by a two-compartment model that assumes elimination only from the sampling compartment, with a rapid distribution phase and a slow elimination phase which predicts that twice daily administration of low dose LT3 in combination with LT4 can predictably increase the serum T3 concentration without significant peaks above the normal range.
Primary hypothyroidism and quality of life
TLDR
The management of primary hypothyroidism and the potential reasons for patient dissatisfaction with treatment are discussed, with little evidence of durable QOL improvements with levothyroxine and liothyronine combination therapy, or from therapy with desiccated thyroid hormone.
Effects of Long-Term Combination LT4 and LT3 Therapy for Improving Hypothyroidism and Overall Quality of Life
TLDR
This first observational study examined the role of combination therapy for 6 years in improving quality of life in a subset of a hypothyroid population without adverse effects and cardiac mortality and compared between the two forms of therapy: synthetic and natural.
...
...

References

SHOWING 1-10 OF 41 REFERENCES
Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine.
TLDR
The substitution of L-T(3) for L-t(4) at equivalent doses reduced body weight and resulted in greater thyroid hormone action on the lipid metabolism, without detected differences in cardiovascular function or insulin sensitivity.
A comparison of thyroxine and desicatted thyroid in patients with primary hypothyroidism.
Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials.
TLDR
T(4) monotherapy should remain the treatment of choice for clinical hypothyroidism, and no difference was found in the effectiveness of combination vs. monotherapy in the following symptoms.
Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial.
TLDR
Treatment of primary hypothyroidism with combination levothyroxine plus liothyronine combined therapy demonstrated no beneficial changes in body weight, serum lipid levels, Hypothyroid symptoms as measured by a HRQL questionnaire, and standard measures of cognitive performance.
L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial.
TLDR
L-Thyroxine therapy may be useful for patients with subclinical hypothyroidism with abnormal myocardial contractility or symptoms consistent with mild hypothy thyroid hormone action, or both.
Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial.
TLDR
Patients preferred combined LT4/LT3 therapy to usual LT4 therapy, but changes in mood, fatigue, well-being, and neurocognitive functions could not satisfactorily explain why the primary outcome was in favor of LT4 /LT3 combination therapy.
Does a combination regimen of thyroxine (T4) and 3,5,3'-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial.
TLDR
The current data do not support the routine use of combined T(3) and T(4) therapy in hypothyroid patients with depressive symptoms and no improvement in self-rated mood and well-being scores is reported.
Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism.
TLDR
It is concluded that in the doses used in this study, combined T(4)/T(3) treatment does not improve well-being, cognitive function, or quality of life compared with T( 4) alone.
Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial.
TLDR
Small changes in T(4) dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life, despite the expected changes in serum TSH and markers of thyroid hormone action.
Stability, Effectiveness, and Safety of Desiccated Thyroid vs Levothyroxine: A Rebuttal to the British Thyroid Association
TLDR
The Committee, the BTA, Escobar-Morreale et al., and Grozinsky-Glasberg et al. are all called upon to correct their false statements of fact as well as their unbalanced presentations of data relevant to their conclusions.
...
...